Search Results
Your search for The ASCO Post,The ASCO Post matches 17277 pages
Showing 301 - 350Accelerated Approval Granted to Zanidatamab-hrii for HER2-Positive Biliary Tract Cancer
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also...
Oral Liquid Imatinib Approved by the FDA in Leukemia
The U.S. Food and Drug Administration (FDA) recently has approved an oral solution of the tyrosine kinase inhibitor, imatinib mesylate, called Imkeldi, to treat certain types of leukemia and other cancers. The new solution is an advanced liquid formulation of imatinib designed to provide dosing...
Cetuximab vs Durvalumab in Treatment of Head and Neck Cancers
Durvalumab, an immune checkpoint inhibitor, has shown activity in treating a wide range of cancers and has been proposed as a potentially safer and more effective option than cetuximab, according to Loren K. Mell, MD, Professor and Vice Chair of Clinical and Translational Research at University of ...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
On December 4, 2024, the U.S. Food and Drug Administration approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Efficacy was evaluated in ADRIATIC...
IMF Welcomes Newly Elected Board of Directors Members
The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman;...
Updated Findings in Preventive Breast Cancer Vaccine Study
Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting.1 According to researchers, including principal...
ASH Announces Recipients of 2024 ASH Advocacy Awards
The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on issues of importance to hematology research and practice at the 2024 ASH Annual Meeting &...
FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with the following types of lung and pancreatic cancers: advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)...
Potential Cancer Vaccine Target Uncovered in E coli Bacteria
Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...
Prior Authorization Delays May Lead to Severe Consequences for Patients With Cancer
A recent nationwide survey has confirmed that prior authorization may cause treatment delays, abandoned treatments, hospitalizations, and deaths among patients with cancer, according to an executive summary published by the American Society for Radiation Oncology (ASTRO). The findings may reinforce ...
Temozolomide Plus Radiotherapy for Low-Grade Gliomas
Based on the phase III E3F05 trial, conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), the combination of radiation therapy and temozolomide appeared to be more effective than radiotherapy alone in the treatment of low-grade gliomas. The trial followed 172 patients for more than 10...
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma
Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...
Study Highlights From MD Anderson Researchers
Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...
Study Evaluating Lung Cancer Screening Program Receives Margulis Award for Scientific Excellence
The 2024 Alexander R. Margulis Award for Scientific Excellence honored the authors of a 20-year follow-up study on the International Early Lung Cancer Action Program (I-ELCAP). The Margulis Award was presented recently during the 2024 Radiological Society of North America (RSNA) Scientific Assembly ...
Understanding the Link Between Obesity and Cancer
Worldwide, more than a billion people have obesity—including 650 million adults, 340 million adolescents, and 39 million children1—a rate that has nearly doubled since 1980.2 In the United States alone, about two out of three adults are overweight or have obesity, and one out of three have...
Impact of Menopausal Status on Long-Term Benefit From Antihormonal Treatment in Women With Breast Cancer
New research has shown that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, whereas the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through menopause. The results were reported in the Journal of the ...
Regional, Racial, Economic Disparities in Air Pollution–Related Cancer Risk May Be Improving but Still Persist
Investigators report they have uncovered patterns in the risk of cancer associated with lifetime exposure to air pollution and how this risk may have changed over time, in a recent study published by Hurbain et al in Environmental Science & Technology. The findings could build on the scientific ...
Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy
Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...
Could SARS–CoV-2 Be an Oncogenic Agent and Cancer Initiator?
It’s not news that some viruses, including human papillomavirus, human immunodeficiency virus, Epstein-Barr, and hepatitis B, can cause or accelerate the development of cancer. But a recent story in The Washington Post about rare cancers being diagnosed in individuals who had previously been...
Obecabtagene Autoleucel in Adults With B-Cell ALL
A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a...
Poor Diets May Increase Risk of Gastrointestinal Cancer
New research may expand on existing evidence that a healthy diet may protect against gastrointestinal cancers and improve disease outcomes, according to a recent study published by Abebe et al in the European Journal of Nutrition. Background Gastrointestinal cancers including esophageal, gastric,...
Lung Cancer CT Screening May Help to Detect Coronary Artery Disease
Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...
Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC
Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...
Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect
Researchers may have uncovered the factors contributing to an increased susceptibility to common infections among patients with cancer receiving checkpoint inhibitors, according to a recent study published by Ogishi et al in Immunity. The findings may provide new insights into immune responses and...
Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology. Dr. Ürün is Professor of Medicine at the Ankara University School of Medicine in Turkey. After...
Ovarian Cancer 2024: Year-at-a-Glance, Part 2
In this second installment of a two-part discussion about ovarian cancer advances for The ASCO Post Newsreels, Ursula A. Matulonis, MD, and Joyce F. Liu, MD, MPH, discuss low-grade serous ovarian carcinoma and an important recently published study. View part 1 of the program to hear them discuss...
Ovarian Cancer 2024: Year at a Glance, Part 1
Over the past year, several important studies in ovarian cancer have been presented at multiple oncology meetings and published in a number of peer-reviewed publications. In this installment of a two-part discussion for The ASCO Post Newsreels, Ursula A. Matulonis, MD, and Joyce F. Liu, MD, MPH,...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Peer Support Intervention May Help Improve Psychological Outcomes Among Patients With Cancer in Low-Resource Settings
Researchers have found that the cancer peer support program Stronger Together may provide critical social support to patients with cancer, particularly in low-resource settings in low- and middle-income countries, according to a recent study published by Le et al in JCO Global Oncology. Background...
FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types
The U.S. Food and Drug Administration (FDA) announced the approval of imatinib (Imkeldi) oral solution, the first oral liquid formulation of the drug to treat certain types of leukemias and other cancers. Background In 2024, an estimated 9,280 patients will be diagnosed with chronic myeloid...
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas
Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...
Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
In earlier issues of The ASCO Post, we shared unique insights from recipients of the International Development and Education Award (IDEA), whose experiences at the 2024 ASCO Annual Meeting (ASCO24) had a profound impact on their professional and personal growth. Here are more reflections from...
NCCN Guidelines Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...
How Functional and Genomic Precision Medicine Are Getting Closer to Matching Each Patient to the Right Therapy
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma
The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with the multikinase inhibitor anlotinib for the first-line treatment of advanced hepatocellular carcinoma...
Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor
The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists
Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a ...
FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also approved ...
Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment
An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...
Firefighters May Be Exposed to Chemicals Associated With Breast Cancer
Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...
Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer
Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast...
ASH to Present 2024 Honorific Awards at Annual Meeting
The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. “ASH is honored to recognize these outstanding...
Project Facilitate: 5 Years of Progress, Outreach, and Service
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Lieutenant Commander Mitchell Chan, PharmD, BCPS, Team Lead and Clinical Analyst, Lieutenant Cameron Wilson, PharmD, BCPS, BCCCP, ...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Suicide-Related Mortality in Male AYA Cancer Survivors
Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open. Cancer is becoming more common among young patients, and cancer...
